Carcinoma
MONDO:0004993A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.
Also known as: epithelioma, Other carcinoma, carcinoma, carcinoma, malignant, epithelial carcinoma, epithelioma malignant, malignant epithelial neoplasm, malignant epithelial tumor
16980 clinical trials for this condition and its sub-types, 224 tagged with Carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Carcinoma
-
Adenocarcinoma 186 trials · 5,262 incl. sub-types
64 sub-types
- Hepatocellular carcinoma 1,046 trials · 1,091 incl. sub-types Sub-types →
- Pancreatic adenocarcinoma 497 trials · 930 incl. sub-types Sub-types →
- Renal cell carcinoma 611 trials · 710 incl. sub-types Sub-types →
- Tubular adenocarcinoma 0 trials · 558 incl. sub-types Sub-types →
- Colorectal adenocarcinoma 247 trials · 548 incl. sub-types Sub-types →
- Gastroesophageal junction adenocarcinoma 507 trials
- Gastric adenocarcinoma 449 trials · 481 incl. sub-types Sub-types →
- Bile duct adenocarcinoma 17 trials · 419 incl. sub-types Sub-types →
- Prostate adenocarcinoma 298 trials Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Serous adenocarcinoma 6 trials · 242 incl. sub-types Sub-types →
- Ovarian adenocarcinoma 12 trials · 231 incl. sub-types Sub-types →
- Clear cell adenocarcinoma 14 trials · 201 incl. sub-types Sub-types →
- Esophageal adenocarcinoma 170 trials · 174 incl. sub-types Sub-types →
- Adenocarcinoma in situ 10 trials · 170 incl. sub-types Sub-types →
- Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types Sub-types →
- Endometrium adenocarcinoma 30 trials · 119 incl. sub-types Sub-types →
- Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types Sub-types →
- Lung adenocarcinoma 114 trials · 117 incl. sub-types Sub-types →
- Gastroesophageal adenocarcinoma 93 trials
- Papillary adenocarcinoma 2 trials · 93 incl. sub-types Sub-types →
- Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types Sub-types →
- Small intestine adenocarcinoma 18 trials · 60 incl. sub-types Sub-types →
- Mucinous adenocarcinoma 18 trials · 57 incl. sub-types Sub-types →
- Adenoid cystic carcinoma 47 trials · 48 incl. sub-types Sub-types →
- Cervical adenocarcinoma 27 trials · 34 incl. sub-types Sub-types →
- Poorly differentiated thyroid gland carcinoma 17 trials
- Acinar cell carcinoma 4 trials · 15 incl. sub-types Sub-types →
- Signet ring cell carcinoma 4 trials · 11 incl. sub-types Sub-types →
- Paget disease 2 trials · 9 incl. sub-types Sub-types →
- Gallbladder adenocarcinoma 9 trials Sub-types →
- Bladder adenocarcinoma 5 trials · 8 incl. sub-types Sub-types →
- Vaginal adenocarcinoma 7 trials Sub-types →
- Cystadenocarcinoma 0 trials · 6 incl. sub-types Sub-types →
- Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types Sub-types →
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Parathyroid gland carcinoma 4 trials
- Pituitary adenocarcinoma 3 trials Sub-types →
- Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types Sub-types →
- Hepatoid adenocarcinoma 2 trials Sub-types →
- Mesonephric adenocarcinoma 2 trials Sub-types →
- Sweat gland carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Follicular variant thyroid gland papillary carcinoma 1 trial
- Micropapillary serous carcinoma 1 trial
- Nasal cavity adenocarcinoma 1 trial
- Seminal vesicle adenocarcinoma 1 trial
- Trabecular adenocarcinoma 1 trial
- Ureter adenocarcinoma 1 trial
- Adenoacanthoma 0 trials
- Epididymal adenocarcinoma 0 trials
- Ethmoid sinus adenocarcinoma 0 trials
- Granular cell carcinoma 0 trials
- Intestinal type adenocarcinoma 0 trials Sub-types →
- Lacrimal gland adenocarcinoma 0 trials Sub-types →
- Maxillary sinus adenocarcinoma 0 trials
- Middle ear adenocarcinoma 0 trials
- Minor salivary gland adenocarcinoma 0 trials Sub-types →
- Rete testis adenocarcinoma 0 trials
- Salivary gland basal cell adenocarcinoma 0 trials
- Scirrhous adenocarcinoma 0 trials
- Submandibular gland adenocarcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Villous adenocarcinoma 0 trials Sub-types →
-
Digestive system carcinoma 25 trials · 4,898 incl. sub-types
16 sub-types
- Carcinoma of liver and intrahepatic biliary tract 36 trials · 1,461 incl. sub-types Sub-types →
- Colorectal carcinoma 305 trials · 1,170 incl. sub-types Sub-types →
- Exocrine pancreatic carcinoma 205 trials · 1,037 incl. sub-types Sub-types →
- Gastric carcinoma 92 trials · 555 incl. sub-types Sub-types →
- Carcinoma of esophagus 76 trials · 509 incl. sub-types Sub-types →
- Gastroesophageal junction adenocarcinoma 507 trials
- Carcinoma of pharynx 3 trials · 457 incl. sub-types Sub-types →
- Oral cavity carcinoma 16 trials · 202 incl. sub-types Sub-types →
- Small intestine carcinoma 19 trials · 105 incl. sub-types Sub-types →
- Gallbladder carcinoma 41 trials · 49 incl. sub-types Sub-types →
- Intestine carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Digestive system mixed adenoneuroendocrine carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Carcinoma of floor of mouth 1 trial · 2 incl. sub-types Sub-types →
- Maxillary sinus carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ameloblastic carcinoma 0 trials
-
Lung carcinoma 137 trials · 3,325 incl. sub-types
10 sub-types
- Non-small cell lung carcinoma 2,725 trials · 2,839 incl. sub-types Sub-types →
- Small cell lung carcinoma 514 trials · 515 incl. sub-types Sub-types →
- Squamous cell lung carcinoma 66 trials · 146 incl. sub-types Sub-types →
- Bronchogenic carcinoma 25 trials Sub-types →
- Lung carcinoma in situ 2 trials · 3 incl. sub-types Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Asbestos-related lung carcinoma 0 trials
- Lung epithelial-myoepithelial carcinoma 0 trials
- Lung hilum carcinoma 0 trials
- Lung inflammatory myofibroblastic tumor 0 trials
-
Breast carcinoma 665 trials · 2,693 incl. sub-types
13 sub-types
- Breast carcinoma by gene expression profile 0 trials · 1,791 incl. sub-types Sub-types →
- Invasive breast carcinoma 325 trials · 413 incl. sub-types Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Breast carcinoma in situ 76 trials · 204 incl. sub-types Sub-types →
- Female breast carcinoma 138 trials Sub-types →
- Male breast carcinoma 22 trials
- Hereditary breast carcinoma 10 trials Sub-types →
- Bilateral breast carcinoma 6 trials · 9 incl. sub-types Sub-types →
- Hormone-resistant breast carcinoma 5 trials
- Sporadic breast cancer 2 trials
- Ehrlich tumor carcinoma 0 trials
- Cribriform carcinoma of breast 0 trials Sub-types →
- Nipple carcinoma 0 trials Sub-types →
-
Squamous cell carcinoma 177 trials · 1,774 incl. sub-types
39 sub-types
- Head and neck squamous cell carcinoma 831 trials · 1,057 incl. sub-types Sub-types →
- Esophageal squamous cell carcinoma 306 trials · 307 incl. sub-types Sub-types →
- Skin squamous cell carcinoma 151 trials · 158 incl. sub-types Sub-types →
- Squamous cell lung carcinoma 66 trials · 146 incl. sub-types Sub-types →
- Human papillomavirus-related squamous cell carcinoma 115 trials · 116 incl. sub-types Sub-types →
- Colorectal squamous cell carcinoma 1 trial · 54 incl. sub-types Sub-types →
- Adenosquamous carcinoma 8 trials · 45 incl. sub-types Sub-types →
- Cervical squamous cell carcinoma 36 trials · 40 incl. sub-types Sub-types →
- Metastatic squamous cell carcinoma 39 trials
- Squamous cell carcinoma of penis 21 trials · 29 incl. sub-types Sub-types →
- Vulvar squamous cell carcinoma 22 trials Sub-types →
- Squamous cell carcinoma of pancreas 3 trials · 13 incl. sub-types Sub-types →
- Bone squamous cell carcinoma 0 trials · 11 incl. sub-types Sub-types →
- Squamous carcinoma in situ 5 trials · 10 incl. sub-types Sub-types →
- Vaginal squamous cell carcinoma 8 trials
- Basaloid squamous cell carcinoma 2 trials · 5 incl. sub-types Sub-types →
- Bladder squamous cell carcinoma 5 trials Sub-types →
- Gastric squamous cell carcinoma 4 trials Sub-types →
- Papillary squamous carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Thyroid gland squamous cell carcinoma 4 trials
- Endometrial squamous cell carcinoma 0 trials · 2 incl. sub-types Sub-types →
- Ovarian squamous cell carcinoma 2 trials
- Urethra squamous cell carcinoma 2 trials Sub-types →
- Keratinizing squamous cell carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Pure squamous carcinoma of the urothelial tract 1 trial
- Scrotum squamous cell carcinoma 1 trial
- Squamous cell carcinoma of the small intestine 1 trial Sub-types →
- Ureter squamous cell carcinoma 1 trial
- Fallopian tube squamous cell carcinoma 0 trials
- Gallbladder squamous cell carcinoma 0 trials Sub-types →
- Prostate squamous cell carcinoma 0 trials Sub-types →
- Pseudoglandular squamous cell carcinoma 0 trials
- Renal pelvis squamous cell carcinoma 0 trials
- Sarcomatoid squamous cell carcinoma 0 trials Sub-types →
- Squamous cell breast carcinoma 0 trials Sub-types →
- Squamous cell carcinoma of liver and intrahepatic biliary tract 0 trials Sub-types →
- Squamous cell carcinoma of the corpus uteri 0 trials
- Thymus squamous cell carcinoma 0 trials Sub-types →
- Trachea squamous cell carcinoma 0 trials Sub-types →
-
Head and neck carcinoma 74 trials · 1,420 incl. sub-types
16 sub-types
- Head and neck squamous cell carcinoma 831 trials · 1,057 incl. sub-types Sub-types →
- Lip and oral cavity carcinoma 96 trials · 260 incl. sub-types Sub-types →
- Oropharyngeal carcinoma 100 trials · 243 incl. sub-types Sub-types →
- Nasopharyngeal carcinoma 211 trials · 212 incl. sub-types Sub-types →
- Hypopharyngeal carcinoma 36 trials · 86 incl. sub-types Sub-types →
- Nasal cavity and paranasal sinus carcinoma 21 trials · 44 incl. sub-types Sub-types →
- Nasal cavity carcinoma 3 trials · 9 incl. sub-types Sub-types →
- Eye carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Pituitary adenocarcinoma 3 trials Sub-types →
- Carcinoma of floor of mouth 1 trial · 2 incl. sub-types Sub-types →
- External ear carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Middle ear carcinoma 1 trial Sub-types →
- Ameloblastic carcinoma 0 trials
- Growth hormone-producing pituitary gland carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
-
Prostate carcinoma 394 trials · 1,324 incl. sub-types
9 sub-types
- Metastatic prostate carcinoma 670 trials
- Castration-resistant prostate carcinoma 480 trials
- Prostate adenocarcinoma 298 trials Sub-types →
- Hormone-resistant prostate carcinoma 30 trials
- Prostate small cell carcinoma 9 trials
- Familial prostate carcinoma 0 trials
- Grade III prostatic intraepithelial neoplasia 0 trials
- Primary prostate urothelial carcinoma 0 trials Sub-types →
- Prostate squamous cell carcinoma 0 trials Sub-types →
-
Renal carcinoma 85 trials · 764 incl. sub-types
3 sub-types
- Renal cell carcinoma 611 trials · 710 incl. sub-types Sub-types →
- Renal pelvis carcinoma 15 trials · 22 incl. sub-types Sub-types →
- Kidney carcinoma in situ 0 trials Sub-types →
-
Neuroendocrine carcinoma 106 trials · 744 incl. sub-types
12 sub-types
- Small cell carcinoma 26 trials · 542 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types Sub-types →
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Goblet cell carcinoma 2 trials
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
-
Transitional cell carcinoma 250 trials · 724 incl. sub-types
9 sub-types
- Urothelial carcinoma 364 trials · 695 incl. sub-types Sub-types →
- Fallopian tube transitional cell carcinoma 12 trials
- Ovarian transitional cell carcinoma 12 trials
- Papillary transitional cell carcinoma 1 trial · 11 incl. sub-types Sub-types →
- Sarcomatoid transitional cell carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Bartholin gland transitional cell carcinoma 1 trial
- Endometrial transitional cell carcinoma 1 trial
- Primary prostate urothelial carcinoma 0 trials Sub-types →
- Transitional cell carcinoma of the corpus uteri 0 trials
-
Urinary bladder carcinoma 394 trials · 673 incl. sub-types
9 sub-types
- Bladder transitional cell carcinoma 131 trials · 411 incl. sub-types Sub-types →
- Superficial urinary bladder carcinoma 77 trials
- Stage IVb bladder cancer 39 trials
- Urinary bladder small cell neuroendocrine carcinoma 9 trials
- Bladder adenocarcinoma 5 trials · 8 incl. sub-types Sub-types →
- Bladder urachal carcinoma 3 trials · 6 incl. sub-types Sub-types →
- Bladder squamous cell carcinoma 5 trials Sub-types →
- Bladder small cell carcinoma 0 trials
- Childhood bladder carcinoma 0 trials
-
Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types
6 sub-types
- Ovarian carcinoma 493 trials · 642 incl. sub-types Sub-types →
- Malignant ovarian serous tumor 5 trials · 203 incl. sub-types Sub-types →
- Ovarian endometrial cancer 4 trials · 89 incl. sub-types Sub-types →
- Ovarian clear cell cancer 30 trials · 51 incl. sub-types Sub-types →
- Mucinous ovarian cancer 2 trials · 16 incl. sub-types Sub-types →
- Malignant ovarian Brenner tumor 2 trials
-
Uterine carcinoma 3 trials · 614 incl. sub-types
9 sub-types
- Cervical carcinoma 257 trials · 317 incl. sub-types Sub-types →
- Endometrial carcinoma 209 trials · 316 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Uterus carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Papillary carcinoma of the corpus uteri 0 trials
- Squamous cell carcinoma of the corpus uteri 0 trials
- Transitional cell carcinoma of the corpus uteri 0 trials
- Undifferentiated carcinoma of the corpus uteri 0 trials
-
Invasive carcinoma 4 trials · 607 incl. sub-types
4 sub-types
- Invasive breast carcinoma 325 trials · 413 incl. sub-types Sub-types →
- Infiltrating urothelial carcinoma 5 trials · 187 incl. sub-types Sub-types →
- Invasive malignant thymoma 4 trials
- Submucosal invasive colon adenocarcinoma 0 trials
-
Peritoneal carcinoma 16 trials · 389 incl. sub-types
3 sub-types
- Primary peritoneal carcinoma 351 trials · 361 incl. sub-types Sub-types →
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Pseudomyxoma peritonei 17 trials
-
In situ carcinoma 25 trials · 318 incl. sub-types
21 sub-types
- Breast carcinoma in situ 76 trials · 204 incl. sub-types Sub-types →
- Adenocarcinoma in situ 10 trials · 170 incl. sub-types Sub-types →
- Bladder carcinoma in situ 30 trials
- Intestine carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Uterus carcinoma in situ 0 trials · 16 incl. sub-types Sub-types →
- Esophagus carcinoma in situ 13 trials
- Squamous carcinoma in situ 5 trials · 10 incl. sub-types Sub-types →
- Skin carcinoma in situ 3 trials · 9 incl. sub-types Sub-types →
- Oral cavity carcinoma in situ 5 trials Sub-types →
- Stomach carcinoma in situ 4 trials Sub-types →
- Lung carcinoma in situ 2 trials · 3 incl. sub-types Sub-types →
- Pharynx carcinoma in situ 0 trials · 2 incl. sub-types Sub-types →
- Larynx carcinoma in situ 1 trial Sub-types →
- Carcinoma in situ of ureter 0 trials
- Carcinoma in situ of urethra 0 trials
- Eye carcinoma in situ 0 trials
- Gall bladder carcinoma in situ 0 trials
- Grade III prostatic intraepithelial neoplasia 0 trials
- Kidney carcinoma in situ 0 trials Sub-types →
- Liver carcinoma in situ 0 trials Sub-types →
- Nasal cavity carcinoma in situ 0 trials
-
Skin carcinoma 35 trials · 283 incl. sub-types
13 sub-types
- Skin squamous cell carcinoma 151 trials · 158 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Skin basal cell carcinoma 52 trials · 60 incl. sub-types Sub-types →
- Skin carcinoma in situ 3 trials · 9 incl. sub-types Sub-types →
- Anal margin carcinoma 1 trial · 6 incl. sub-types Sub-types →
- Skin appendage carcinoma 4 trials · 6 incl. sub-types Sub-types →
- Eyelid carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Borst-Jadassohn intraepidermal carcinoma 0 trials
- Cutaneous mucoepidermoid carcinoma 0 trials
- Labia majora carcinoma 0 trials
- Labia minora carcinoma 0 trials
- Vulvar seborrheic keratosis 0 trials Sub-types →
-
Thyroid gland carcinoma 41 trials · 237 incl. sub-types
11 sub-types
- Differentiated thyroid carcinoma 79 trials · 182 incl. sub-types Sub-types →
- Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types Sub-types →
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Multiple endocrine neoplasia type 2 4 trials · 30 incl. sub-types Sub-types →
- Familial nonmedullary thyroid carcinoma 3 trials · 15 incl. sub-types Sub-types →
- Thyroid gland squamous cell carcinoma 4 trials
- Intrathyroid thymic carcinoma 0 trials
- Thyroid gland cribriform morular carcinoma 0 trials
- Thyroid gland mixed medullary and follicular cell-derived carcinoma 0 trials
- Thyroid gland mucinous carcinoma 0 trials
- Thyroid gland spindle cell tumor with thymus-like differentiation 0 trials
-
Fallopian tube carcinoma 126 trials · 182 incl. sub-types
6 sub-types
- Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types Sub-types →
- Fallopian tube transitional cell carcinoma 12 trials
- Fallopian tube carcinosarcoma 8 trials
- Fallopian tube gestational choriocarcinoma 0 trials
- Fallopian tube squamous cell carcinoma 0 trials
- Hereditary fallopian tube carcinoma 0 trials
-
Secondary carcinoma 1 trial · 169 incl. sub-types
1 sub-type
- Metastatic carcinoma 22 trials · 168 incl. sub-types Sub-types →
-
Bone carcinoma 0 trials · 131 incl. sub-types
7 sub-types
- Metastatic carcinoma in the bone 107 trials
- Paranasal sinus carcinoma 4 trials · 21 incl. sub-types Sub-types →
- Bone squamous cell carcinoma 0 trials · 11 incl. sub-types Sub-types →
- Pituitary adenocarcinoma 3 trials Sub-types →
- Adamantinoma 0 trials Sub-types →
- Growth hormone-producing pituitary gland carcinoma 0 trials
- Osteosarcoma arising in bone Paget disease 0 trials
-
Basal cell carcinoma 112 trials · 121 incl. sub-types
1 sub-type
- Skin basal cell carcinoma 52 trials · 60 incl. sub-types Sub-types →
-
Laryngeal carcinoma 56 trials · 114 incl. sub-types
8 sub-types
- Laryngeal squamous cell carcinoma 72 trials · 77 incl. sub-types Sub-types →
- Glottis carcinoma 6 trials · 10 incl. sub-types Sub-types →
- Carcinoma of supraglottis 1 trial · 2 incl. sub-types Sub-types →
- Larynx carcinoma in situ 1 trial Sub-types →
- Subglottis carcinoma 1 trial Sub-types →
- Laryngeal adenoid cystic carcinoma 0 trials
- Laryngeal mucoepidermoid carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
-
Papillary carcinoma 8 trials · 113 incl. sub-types
5 sub-types
- Papillary adenocarcinoma 2 trials · 93 incl. sub-types Sub-types →
- Papillary transitional cell carcinoma 1 trial · 11 incl. sub-types Sub-types →
- Papillary squamous carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Papillary carcinoma of the cervix uteri 0 trials Sub-types →
- Papillary carcinoma of the corpus uteri 0 trials
-
Large cell carcinoma 2 trials · 87 incl. sub-types
5 sub-types
- Lung large cell carcinoma 11 trials · 37 incl. sub-types Sub-types →
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Nasopharyngeal type undifferentiated carcinoma 2 trials · 3 incl. sub-types Sub-types →
- Salivary gland large cell carcinoma 0 trials
-
Undifferentiated carcinoma 6 trials · 80 incl. sub-types
14 sub-types
- Thyroid gland undifferentiated (anaplastic) carcinoma 35 trials
- Undifferentiated ovarian carcinoma 13 trials
- Endometrial undifferentiated carcinoma 9 trials
- Undifferentiated carcinoma of nasopharynx 7 trials
- Nut midline carcinoma 6 trials
- Sinonasal undifferentiated carcinoma 6 trials
- Undifferentiated carcinoma of esophagus 1 trial
- Undifferentiated carcinoma of liver and intrahepatic biliary tract 1 trial
- Undifferentiated carcinoma of stomach 1 trial
- Undifferentiated pancreatic carcinoma 1 trial Sub-types →
- Salivary gland large cell carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Undifferentiated carcinoma of the corpus uteri 0 trials
- Undifferentiated gallbladder carcinoma 0 trials
-
Mucin-producing carcinoma 0 trials · 58 incl. sub-types
2 sub-types
- Mucinous adenocarcinoma 18 trials · 57 incl. sub-types Sub-types →
- Pancreatic mucinous cystadenoma 1 trial
-
Retroperitoneum carcinoma 0 trials · 52 incl. sub-types
1 sub-type
- Adrenal carcinoma 34 trials · 52 incl. sub-types Sub-types →
-
Vulvar carcinoma 24 trials · 45 incl. sub-types
9 sub-types
- Vulvar squamous cell carcinoma 22 trials Sub-types →
- Vulvar adenocarcinoma 3 trials · 5 incl. sub-types Sub-types →
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Clitoral carcinoma 0 trials
- Labia majora carcinoma 0 trials
- Labia minora carcinoma 0 trials
- Vulva basal cell carcinoma 0 trials
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
- Vulvar seborrheic keratosis 0 trials Sub-types →
-
Thymic carcinoma 41 trials · 44 incl. sub-types
9 sub-types
- Invasive malignant thymoma 4 trials
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Lymphoepithelioma-like thymic carcinoma 0 trials
- Malignant type AB thymoma 0 trials
- Thymic sarcomatoid carcinoma 0 trials
- Thymic undifferentiated carcinoma 0 trials
- Thymus clear cell carcinoma 0 trials
- Thymus gland adenocarcinoma 0 trials Sub-types →
- Thymus squamous cell carcinoma 0 trials Sub-types →
-
Penile carcinoma 9 trials · 35 incl. sub-types
3 sub-types
- Squamous cell carcinoma of penis 21 trials · 29 incl. sub-types Sub-types →
- Paget disease of the penis 0 trials
- Penis basal cell carcinoma 0 trials
-
Sarcomatoid carcinoma 1 trial · 26 incl. sub-types
8 sub-types
- Sarcomatoid renal cell carcinoma 15 trials
- Lung sarcomatoid carcinoma 3 trials · 7 incl. sub-types Sub-types →
- Sarcomatoid transitional cell carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Pleomorphic carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectal sarcomatoid carcinoma 0 trials
- Sarcomatoid basal cell carcinoma 0 trials
- Sarcomatoid squamous cell carcinoma 0 trials Sub-types →
- Thymic sarcomatoid carcinoma 0 trials
-
Vaginal carcinoma 12 trials · 22 incl. sub-types
2 sub-types
- Vaginal squamous cell carcinoma 8 trials
- Vaginal adenocarcinoma 7 trials Sub-types →
-
Carcinoma of urethra 2 trials · 21 incl. sub-types
5 sub-types
- Urethra transitional cell carcinoma 17 trials Sub-types →
- Urethra adenocarcinoma 1 trial · 2 incl. sub-types Sub-types →
- Urethra squamous cell carcinoma 2 trials Sub-types →
- Littre gland carcinoma 0 trials Sub-types →
- Carcinoma in situ of urethra 0 trials
-
Ureter carcinoma 1 trial · 19 incl. sub-types
6 sub-types
- Ureter transitional cell carcinoma 16 trials Sub-types →
- Ureter adenocarcinoma 1 trial
- Ureter small cell carcinoma 1 trial
- Ureter squamous cell carcinoma 1 trial
- Carcinoma in situ of ureter 0 trials
- Regional ureteric cancer 0 trials
-
Choroid plexus carcinoma 11 trials
1 sub-type
-
Basaloid carcinoma 0 trials · 5 incl. sub-types
2 sub-types
- Basaloid squamous cell carcinoma 2 trials · 5 incl. sub-types Sub-types →
- Basaloid large cell lung carcinoma 0 trials
-
Cribriform carcinoma 1 trial · 4 incl. sub-types
2 sub-types
- Salivary duct carcinoma 3 trials
- Cribriform carcinoma of breast 0 trials Sub-types →
-
Malignant myoepithelioma 2 trials
1 sub-type
- Malignant breast myoepithelioma 0 trials
-
Combined carcinoid and adenocarcinoma 0 trials · 2 incl. sub-types
1 sub-type
- Goblet cell carcinoma 2 trials
-
Carcinoma ex pleomorphic adenoma 1 trial
2 sub-types
-
Trachea carcinoma 1 trial
3 sub-types
- Trachea mucoepidermoid carcinoma 0 trials
- Trachea squamous cell carcinoma 0 trials Sub-types →
- Tracheal adenoid cystic carcinoma 0 trials
-
Scrotal carcinoma 0 trials · 1 incl. sub-types
3 sub-types
- Scrotum squamous cell carcinoma 1 trial
- Scrotum Paget disease 0 trials
- Scrotum basal cell carcinoma 0 trials
-
Krebs 2 carcinoma 0 trials
-
Comedocarcinoma 0 trials
-
Epithelial-myoepithelial carcinoma 0 trials
2 sub-types
-
Glycogen-rich carcinoma 0 trials
1 sub-type
-
Lipid-rich carcinoma 0 trials
1 sub-type
- Lipid-rich breast carcinoma 0 trials
-
Lymph node carcinoma 0 trials
Most studied deeper sub-types
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Experimental vaccine aims to stop lung cancer from coming back
Disease control PausedThis trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Chemotherapy delivered directly to abdomen shows promise in early trial
Disease control OngoingThis early-phase trial tests a combination of three drugs for people whose appendix or colon cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). After surgery to remove visible tumors, patients receive chemotherapy directly into the abdomen (oxaliplatin) p…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Promising combo may delay drug resistance in lung cancer patients
Disease control OngoingThis study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug DM001 take on advanced solid tumors?
Disease control OngoingThis early-stage trial tests an experimental drug called DM001 in people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers that have progressed on standard treatment. The main goals are to find a safe dose, identify side effe…
Phase 1 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets liver cancer in clinical trial
Disease control OngoingThis study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…
Phase 2 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
Disease control OngoingThis phase II trial is investigating whether giving immunotherapy before surgery can boost the immune system's attack on head and neck squamous cell carcinoma. Participants receive atezolizumab alone or combined with other immune-modulating agents, then undergo surgery. The study…
Phase 2 • Sponsor: Alain Algazi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for lung cancer patients whose current drug stops working
Disease control OngoingThis study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New combo therapy shows promise for Drug-Resistant lung cancer
Disease control OngoingThis phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
Disease control OngoingThis phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control PausedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Phase 2/3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with resistant tumors: drug combo enters safety trial
Disease control OngoingThis early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare kidney cancer: drug combo shows promise in late-stage trial
Disease control OngoingThis phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo targets metastatic tumors in early safety trial
Disease control OngoingThis early-phase study tests whether a new drug called AZD1390 is safe when given together with a precise type of radiation therapy (SBRT) for people whose solid tumors have spread to other parts of the body. The study involves 54 adults with metastatic cancer. The main goal is t…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Custom-Made immune cells take on incurable tumors
Disease control OngoingThis early-phase study tests a personalized treatment for people with incurable cancers. Doctors take a patient's own immune cells, engineer them to recognize unique markers on their tumor, and infuse them back along with drugs that boost the immune response. The goal is to see i…
Phase 1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThis phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Phase 1/2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy targets rare, aggressive kidney cancer
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and relatlimab, can shrink or control a rare and aggressive kidney cancer called renal medullary carcinoma (RMC). The trial includes 30 adults whose cancer has spread or cannot be removed by surgery. The goal is to see h…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a vaccine help fight throat cancer? new trial tests promising combo
Disease control OngoingThis study tests whether a vaccine (PDS0101) given alone or with an immunotherapy drug (pembrolizumab) can shrink HPV-related throat tumors before surgery. About 20 adults with advanced cancer that has spread to nearby lymph nodes will receive the treatment. The goal is to see if…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Supercharged immune cells take on incurable tumors
Disease control OngoingThis early-phase trial tests a new approach for people with advanced epithelial cancers that cannot be cured. Researchers take a patient's own immune cells, genetically engineer them to recognize unique cancer markers, and infuse them back along with two drugs that boost the immu…
Phase 1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy aims to halt merkel cell cancer spread
Disease control OngoingThis study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…
Phase 1/2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising combo aims to tame relapsed childhood cancers
Disease control OngoingThis study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase 1/2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Blue dye gel shows promise for treating inoperable skin cancer
Disease control By invitation onlyThis study tests whether a special blue dye gel (methylene blue) can safely shrink skin cancer tumors and help wounds heal in people who cannot have surgery or radiation. About 20 adults with advanced squamous cell carcinoma will apply the gel every two days for a month, followed…
Phase 3 • Sponsor: Daryoush Hamidi Alamdari, PhD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Last-Resort drug access for rare lung cancer patients
Disease control Expanded access (ended)This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …
Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail aims to fight advanced liver cancer
Disease control OngoingThis phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy combo aims to stop lung cancer return after chemoradiation
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help prevent cancer progression in people with limited-stage small cell lung cancer who have completed chemoradiation. About 730 participants will receive either the drug combin…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control OngoingThis early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Weekly vs. Every-3-Week cisplatin: which is safer for head and neck cancer?
Disease control OngoingThis phase 2 trial tests whether giving cisplatin chemotherapy weekly alongside radiation causes fewer severe side effects than the standard every-3-week schedule in people with head and neck cancer. About 80 participants will receive one of the two schedules. The study also look…
Phase 2 • Sponsor: Susanne Arnold • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called SI-B001, a bispecific antibody that targets two proteins (EGFR and HER3) found on many cancer cells. The study involves about 60 adults with advanced epithelial tumors that cannot be cured or have no standard treatment. The main goal…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Lung cancer combo therapy study pulled before it started
Disease control CancelledThis study was designed to test a combination of chemotherapy drugs (cisplatin and docetaxel) with radiation therapy for people with advanced non-small cell lung cancer that could not be removed by surgery. The plan included chemotherapy before, during, and after radiation. Howev…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 16:19 UTC
-
New triple therapy aims to stall advanced kidney cancer
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug cabozantinib to two immunotherapies (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 participants with intermediate- or poor-risk disease are randomly …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Urine test may spare bladder cancer patients from frequent scopes
Diagnosis OngoingThis study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…
Sponsor: Oslo University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
AI tool aims to sharpen colonoscopy diagnoses
Diagnosis OngoingThis study tests a computer program that analyzes colonoscopy images to help doctors decide if a growth (polyp) is an adenoma (pre-cancerous) or not. The software gives a probability score for each lesion. The trial involves 1,178 adults and compares the software's results to lab…
Sponsor: WAYCEN Inc • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Robotic surgery or radiation? new study compares which is better for throat cancer patients' quality of life
Symptom relief OngoingThis study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…
Sponsor: Christian von Buchwald • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Scientists track immune cells to unlock immunotherapy secrets in kidney and bladder cancers
Knowledge-focused OngoingThis study looks at how immune cells change in the blood of people with kidney or bladder cancer during immunotherapy treatment. Researchers will measure different immune cells and tumor cells in blood samples from 67 participants. The goal is to better understand how the immune …
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Radiation study seeks samples, not a cure
Knowledge-focused By invitation onlyThis study collects blood and urine samples from 1,000 adults receiving radiation therapy for cancer. Researchers want to learn how radiation affects gene activity in white blood cells, damages red blood cells, and changes hormone levels. No new treatment is being tested—this is …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
NCI launches 15-Year checkup for cell therapy volunteers
Knowledge-focused By invitation onlyThis study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
New PET scans reveal how Immune-Boosting drugs target tumors
Knowledge-focused OngoingThis study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Ovarian cancer drug trial aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New screening could open door to T-Cell therapy for Hard-to-Treat cancers
Knowledge-focused OngoingThis study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC